Parkinson Disease and Parkinsonism Panel
Use
This panel is intended for individuals with a clinical or suspected diagnosis of Parkinson disease or parkinsonism. It includes those suspected to have various onset ages such as infantile, juvenile, early, or late onset Parkinson disease. Detecting genetic mutations in this panel can aid in confirming a diagnosis, guiding treatment decisions, and informing family planning.
Special Instructions
Test options include Exome-Wide CNV Analysis as an add-on for $250, available only for PGxome-based or custom panel orders. STANDARD test requisition forms must be completed for institutional orders. The test includes NGS with CNV analysis, suitable for blood, DNA, buccal, saliva, and tissue specimens depending on the platform used. Contact PreventionGenetics for support and assistance with test selection and interpretation.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration. The performance characteristics were validated by PreventionGenetics in accordance with CAP and CLIA regulations. Results may be impacted by the quality of clinical information provided, which is required for variant interpretation.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
14-28 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided